ClinicalTrials.gg

Program

Midodrine

Also written as “Midodrine HCl Tablets 5 mg”, “Midodrine HCl” and “Dexmedetomidine and Midodrine”.

Its studies are mostly in Hypotension, Orthostatic · Alzheimer Disease · Hypotension, led by 4 companies.

Furthest: phase 4, since Sep 20, 200210 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda50 open or runningphase 4since Sep 20, 2002Sep 20, 2002none ahead
Viatris30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Applied Cognition10 open or runningphase 2since Feb 15, 2026Feb 15, 2026none ahead
Nimedical10 open or runningphase 4since Feb 8, 2017Feb 8, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 20, 2002First studies: 2 phase 4 studies in Hypotension, OrthostaticNew to TakedaTakeda · NCT00046163, NCT00046475
  2. Nov 8, 2007Phase 4 study in Hypotension, OrthostaticTakeda · NCT00555880 · 24 enrolled · United States
  3. Mar 30, 2008Viatris's first studies: 3 phase 1 studies in HealthyNew to ViatrisViatris · NCT00650364, NCT00650013, NCT00648440
  4. Jan 18, 20122 phase 4 studiesTakeda · NCT01518946, NCT01515865
  5. Feb 8, 2017Nimedical's first study: phase 4 study in Intradialytic HypotensionNew to NimedicalNimedical · NCT03080441 · 35 enrolled
  6. Feb 15, 2026Applied Cognition's first study: phase 2 study in Alzheimer DiseaseNew to Applied CognitionApplied Cognition · NCT07432997 · 31 enrolled · United States

TargetBeta

“Adrenergic receptor alpha-1 agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
TamsulosinruleBoehringer Ingelheimphase 460
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
PrazosinrulePfizerphase 34

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07432997Alzheimer Disease · United States2CompletedApplied CognitionSep 13, 202431
NCT03080441Intradialytic Hypotension4UNKNOWNNimedicalApr 1, 201735
NCT01518946Hypotension, Orthostatic · United States4CompletedTakedaJun 22, 201324
NCT01515865Symptomatic Orthostatic Hypotension · United States, Czechia, Poland and more4CompletedTakedaNov 11, 201398
NCT00650364Healthy · United States1CompletedViatrisAug 200238
NCT00650013Healthy · United States1CompletedViatrisAug 200223
NCT00648440Healthy · United States1CompletedViatrisNov 200236
NCT00555880Hypotension, Orthostatic · United States4CompletedTakedaMar 21, 200524
NCT00046475Hypotension, Orthostatic · United States4CompletedTakedaNov 24, 1999140
NCT00046163Hypotension, Orthostatic · United States4TerminatedTakedaAug 6, 2003150

How it is read

Names in the registry

  • “Midodrine HCl Tablets 5 mg”, 3 entries
  • “Midodrine HCl”, 2 entries
  • “Dexmedetomidine and Midodrine”, 1 entry
  • “midodrine hydrochloride (ProAmatine®)”, 1 entry
  • “Midodrine hydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.